| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 380 | 590 | 1,180 | 670 | 1,700 |
| Sales Growth | -35.59% | -50.00% | +76.12% | -60.59% | +33.86% |
| Net Income | -28,710 | -30,570 | -26,350 | -28,980 | -27,400 |
| Net Income Growth | +6.08% | -16.02% | +9.08% | -5.77% | -10.71% |
Absci Corp
(ABSI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
Fiscal Year End Date: 12/31